Drug Discovery

SandboxAQ is making its drug discovery models accessible through Claude, aiming to broaden use beyond computing specialists.

OpenAI debuts GPT-Rosalind, a limited-access model designed to accelerate biological research and drug discovery workflows.

Amazon Web Services launched Amazon Bio Discovery, an agentic AI application with 40+ biology models to speed early-stage drug discovery for scientists.

Novo Nordisk will integrate OpenAI's AI across its operations to accelerate drug development, including obesity and diabetes treatments.

Anthropic purchased stealth AI biotech startup Coefficient Bio for $400M in stock, marking a major push into AI-driven drug discovery and biological research.

Isomorphic Labs launches IsoDDE, an AI drug design engine that more than doubles AlphaFold 3's accuracy in predicting protein-ligand structures and binding affinities.

Eli Lilly, GSK, and Pfizer announce multi-year AI partnerships with startups Chai Discovery, Noetik, and Boltz for biologics design, cancer prediction, and drug discovery applications.

The pharmaceutical industry is poised for a paradigm shift from Research & Development (R&D) to Research & Prediction (R&P), with agentic AI expected to deliver the first fully predictive drug development pipeline by 2026.

Nvidia and pharmaceutical giant Eli Lilly establish co-innovation lab in San Francisco combining compute resources and scientific expertise to accelerate medicine development.